Arvinas
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 445
- Market Cap
- $1.7B
- Website
- http://www.arvinas.com
- Introduction
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
- Conditions
- KRAS G12D MutationAdvanced Solid Cancer
- Interventions
- Drug: ARV-806
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Arvinas Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT07023731
- Locations
- 🇺🇸
Clinical Trial Site, Fairfax, Virginia, United States
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Conditions
- Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Arvinas Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT06393738
- Locations
- 🇪🇸
Clinical Trial Site, Salamanca, Spain
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Arvinas Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT05549505
- Locations
- 🇪🇸
Clinical Trial Site, Zaragoza, Spain